Animas IR 1200 - the world's smallest full feature insulin pump - receives FDA approval
November 4, 2003 - Frazer, PA - Animas Corporation has received approval from the U.S. Food and Drug Administration for the Animas IR 1200 insulin pump. This approval marks a major milestone for Animas, as well as the diabetes industry. The IR 1200 is the smallest, full-feature insulin pump available today.
The IR 1200, Animas' third generation of insulin pumps, has several features including low basal insulin delivery, largest screen display, CarbSmartTM, long battery life, non-volatile RAM and waterproof at 12 feet for 24 hours.
"With the introduction of the IR 1200, Animas continues to break new ground in safety and performance," explains Dr. Katherine Crothall, CEO.
"Since the company was founded, we have worked with world-class engineers, healthcare professionals and our patients in order to design an intuitive and feature-rich pump, with every detail designed to enhance pump therapy. The FDA's approval is a great opportunity for people with insulin-requiring diabetes, as well as our business."
"Our commitment to quality and care is evident in many ways, from our 24/7 customer support team to meeting the most rigorous safety and quality standards in the industry," Dr. Crothall continues. "With pump therapy becoming a more popular choice over insulin injections, it is our goal to make pump therapy easier. The IR 1200 makes that goal a reality."
In addition to the introduction of the IR 1200, Animas continues to work on the development of its implantable glucose sensor which will provide accurate and continuous glucose measurement. Preliminary human trials are expected to begin in 2003.
The Animas IR 1200 insulin pump in blue. Other colors include silver and black. The smaller IR 1200 holds 200 units of insulin.
About Animas Corporation: Animas, a leading maker of insulin infusion pumps and related products, is dedicated to improving diabetes management and making insulin pump therapy easier for patients with insulin requiring diabetes and healthcare professionals through product innovation, exemplary customer support and superior customer education. For more information on Animas, visit www.animascorp.com or call Animas Corporation at 877-937-7867.
About Diabetes: With diabetes at epidemic levels and an imminent cure still just a dream, the need for better diabetes management has become paramount in treating the disease. Diabetes is the fifth deadliest disease in the country and now one of the most costly health problems. Health care costs and lost production costs associated with diabetes amounts to $98 billion annually.
Background: A long-term study, known as the Diabetes Control and Complications Trial (DCCT), showed that the long-term complication rate of diabetes could be substantially reduced with intensive therapy which requires a patient with diabetes to measure his blood sugar as much as 5 to 7 times a day, and either take a minimum of 4 insulin shots daily, or be on an insulin infusion pump.
610-644-8990, ext. 1157
Last Updated: Thursday November 06, 2003 10:10:36
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by Children With Diabetes, Inc, which is responsible for its contents.
© Children with Diabetes, Inc. 1995-2014. Comments and Feedback.